HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS		QUICK SEARCH:   [advanced] Author: Keyword(s): Year:  Vol:  Page:

This Article Abstract Full Text (PDF) Alert me when this article is cited Alert me if a correction is posted Citation Map Services Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Request Permissions Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Zhai, Y. Articles by Kupiec-Weglinski, J. W. Search for Related Content PubMed PubMed Citation Articles by Zhai, Y. Articles by Kupiec-Weglinski, J. W.

CXCR3⁺CD4⁺ T Cells Mediate Innate Immune Function in the Pathophysiology of Liver Ischemia/Reperfusion Injury¹

Yuan Zhai^*, Xiu-da Shen^*, Wayne W. Hancock, Feng Gao^*, Bo Qiao^*, Charles Lassman, John A. Belperio, Robert M. Strieter, Ronald W. Busuttil^* and Jerzy W. Kupiec-Weglinski^2,*

^* The Dumont-University of California Los Angeles (UCLA) Transplant Center, Department of Surgery, Division of Liver and Pancreas Transplantation, Department of Pathology and Laboratory Medicine, Department of Medicine, Division of Pulmonary and Critical Care Medicine, David Geffen School of Medicine, UCLA, Los Angeles, CA 90095; and Biesecker Pediatric Liver Center and Department of Pathology and Laboratory Medicine, Children’s Hospital of Philadelphia and University of Pennsylvania, Philadelphia, PA 19104

	Abstract

Top Abstract Introduction Materials and Methods Results Discussion Disclosures References

 
Ischemia-reperfusion injury (IRI), an innate immune-dominated inflammatory response, develops in the absence of exogenous Ags. The recently highlighted role of T cells in IRI raises a question as to how T lymphocytes interact with the innate immune system and function with no Ag stimulation. This study dissected the mechanism of innate immune-induced T cell recruitment and activation in rat syngeneic orthotopic liver transplantation (OLT) model. Liver IRI was induced after cold storage (24–36 h) at 4°C in University of Wisconsin solution. Gene products contributing to IRI were identified by cDNA microarray at 4-h posttransplant. IRI triggered increased intrahepatic expression of CXCL10, along with CXCL9 and 11. The significance of CXCR3 ligand induction was documented by the ability of neutralizing anti-CXCR3 Ab treatment to ameliorate hepatocellular damage and improve 14-day survival of 30-h cold-stored OLTs (95 vs 40% in controls; p < 0.01). Immunohistology analysis confirmed reduced CXCR3⁺ and CD4⁺ T cell infiltration in OLTs after treatment. Interestingly, anti-CXCR3 Ab did not suppress innate immune activation in the liver, as evidenced by increased levels of IL-1, IL-6, inducible NO synthase, and multiple neutrophil/monokine-targeted chemokine programs. In conclusion, this study demonstrates a novel mechanism of T cell recruitment and function in the absence of exogenous Ag stimulation. By documenting that the execution of innate immune function requires CXCR3⁺CD4⁺ T cells, it highlights the critical role of CXCR3 chemokine biology for the continuum of innate to adaptive immunity in the pathophysiology of liver IRI.

	Introduction

Top Abstract Introduction Materials and Methods Results Discussion Disclosures References

 
Ischemia-reperfusion (IR)³ injury (IRI) is a common cause of hepatocellular dysfunction that may develop in various clinical settings, including low flow states, surgical procedures, or during organ procurement for transplantation (1, 2). Indeed, IRI, an Ag-independent component of the harvesting insult represents a serious problem affecting transplantation outcome as it causes up to 10% of early organ failure, and increases the risk of both acute and chronic rejection (3, 4). Additionally, because of the higher susceptibility of marginal livers to ischemia, IRI contributes to the acute shortage of livers available for transplantation. Thus, minimizing the adverse effects of IRI might increase the donor pool and the number of patients that can successfully undergo liver transplantation.

The ischemic insult activates Kupffer cells, and to a lesser degree endothelial cells and hepatocytes, leading to the formation of reactive oxygen species and secretion of proinflammatory cytokines/chemokines (5, 6). Oxidant stress directly damages endothelial cells and hepatocytes, while the soluble factors are responsible for neutrophil, monocyte, and T cell, recruitment. Putative mechanisms by which IR activates components of the innate immune system remain unclear. We have recently shown that innate immune receptor TLR4 signaling is essential for the development of hepatocellular damage in a murine warm liver IRI model (7). Although T lymphocytes have historically been thought marginal to the process, recent studies have documented their key role in the early phase of IRI (8). Thus, T cell-deficient and CD4-deficient mice were protected from IRI, despite normal levels of neutrophil and macrophage infiltration (9, 10, 11, 12). Moreover, adoptive transfer of T cells, particularly the CD4⁺ T subset, restored IRI in otherwise T cell-deficient hosts. The question thus arises as to how T cells become involved in the absence of exogenous Ags, and how T cells function in the pathogenesis of IRI?

The current study documents that liver IR triggers intrahepatic production of multiple chemokines, in particular CXCL9, 10, 11, which target selectively CXCR3⁺CD4⁺ T cells. Indeed, the application of anti-CXCR3 Ab ameliorated hepatocellular damage with resultant increased survival of syngeneic orthotopic liver transplant (OLT) recipients after extended periods of cold preservation. Interestingly, anti-CXCR3 Ab did not inhibit IR-induced innate immune activation. With the immunohistology demonstration that intrahepatic CD4⁺CXCR3⁺ lymphocytes were selectively depleted in the protected livers, this study reveals a novel mechanism by which CXCR3 T cells mediate the innate immune function leading to hepatocellular damage, and highlights the critical role of CXCR3 chemokines in the pathophysiology of liver IRI.

	Materials and Methods

Top Abstract Introduction Materials and Methods Results Discussion Disclosures References

 
Rats

LEW rats (250–300 g) were obtained from Harlan Sprague Dawley, housed in the University of California (Los Angeles, CA) (UCLA) animal facility under specific pathogen-free conditions, and received human care according to the criteria outlined in the "Guide for the Care and Use of Laboratory Animals" prepared by the National Academy of Sciences and published by the National Institute of Health (National Institutes of Health publication 86-23, revised 1985).

Cold ischemia and syngeneic OLT

Livers were harvested from LEW rats, stored for 0, 24, 30, or 36 h at 4°C in University of Wisconsin (UW) solution, and then transplanted into syngeneic LEW recipients, with revascularization without hepatic artery reconstruction (13, 14). In the treatment group, LEW livers were stored at 4°C in UW solution for 30 h before transplantation into syngeneic rats that were treated with polyclonal rabbit-anti-murine CXCR3 or normal rabbit serum (24 h before and at the time of OLT; 1 ml i.v.). The production, characterization and in vivo efficacy of this anti-CXCR3 serum in mouse models have been described (13). However, this antiserum cross-reacts with rat CXCR3. Indeed, the sequence of murine peptide (N-terminal 16-mer of CXCR3: PYDYGENESDFSDSPP) used to generate polyclonal Ab is identical with that of the rat CXCR3 peptide. Hence, we assume that the infused serum binds rat and mouse CXCR3 with similar specificity. OLT recipients were followed for survival and serum alanine aminotransferase (sALT) levels, an indicator of hepatocellular injury. Separate groups of rats were sacrificed at 4 or 24 h, and OLT samples were collected for RNA/protein isolation, as well as for histology/immunohistology evaluations.

Immunopathology

For histological examination, portions of each liver were fixed in formalin, paraffin-embedded and stained by H&E. For immunohistology, cryostat sections of snap-frozen samples were stained using mouse anti-rat mAbs directed against T cell subsets (BD Pharmingen), and polyclonal Abs to rat IFN--inducible protein-10 (IP-10) and CXCR3 (Santa Cruz Biotechnology). Labeling was detected using an Envision immunoperoxidase kit (DakoCytomation) and sections were counterstained with hematoxylin. Control sections were incubated with isotype-matched mAbs, purified rabbit or goat IgG, and polyclonal Abs preabsorbed overnight using corresponding IP-10 and CXCR3 peptides (Santa Cruz Biotechnology). Quantitation of CD4⁺, CD8⁺, and CXCR3⁺ cells was performed blindly, using 10 consecutive high power fields of each graft. Sections were cut from two different levels per graft and three grafts per group per time point were evaluated; data were expressed as mean ± SD cells per field.

cDNA microarray and data analysis

Total tissue RNA was prepared using TRIzol reagent (Invitrogen Life Technologies). Sample preparation for cDNA microarray and microarray processing were performed by the UCLA Microarray Core, using Rat Genome U34A gene chips from Affymetrix. The raw data was analyzed using the Gene Chip Analysis Suite (Affymetrix), and expression data were imported into Microsoft Excel 2000 for further analysis and plotting. Microarray data were normalized to the housekeeping gene (GAPDH). To identify the genes significantly increased by IR, genes with "absent" call in ischemic sample chips were eliminated when comparing two experimental conditions, average expression levels were calculated and fold increases between groups were used to sort data. The cytokine/chemokine expression grid was made with GeneCluster 2 (Whitehead Institute Center for Genome Research) using a subset expression database of cytokine/chemokine genes selected from the U34A database.

Quantitative RT-PCR

Five micrograms of RNA was reverse-transcribed into cDNA using random hexamers and Omniscript reverse transcriptase (Qiagen). Quantitative PCR was performed using the DNA Engine with Chromo 4 Detector (MJ Research). In a final reaction volume of 25 µl, the following were added: 1x SuperMix (Platinum SYBR Green qPCR kit; Invitrogen Life Technologies), cDNA and 0.5 mM of each primer. Amplification conditions were: 50xC (2 min), 95°C (5 min) followed by 50 cycles of 95°C (15 s), 60°C (30 s). Primers used to amplify a specific fragment of -actin, CXCL9, 10, 11, IL-1, inducible NO synthase (iNOS), RANTES, CD86, MCP-1, MIP-2 are listed (Table I).

Protein was extracted from liver samples with PBS/TDS buffer (50 mM Tris, 150 mM NaCl, 0.1% SDS, 1% sodium deoxycholate, and 1% Triton X-100 (pH 7.2)). Proteins (30 µg/sample) in SDS-loading buffer (50 mM Tris, (pH 7.6), 10% glycerol, 1% SDS) were subjected to 20% SDS-PAGE and transferred to nitrocellulose membrane (Bio-Rad). The gel was stained with Coomassie blue to document equal protein loading. Membranes were blocked with 5% dry milk and 0.1% Tween 20 (USB) in PBS and incubated with rabbit anti-rat IP-10 (Cell Science) or -actin Ab (Santa Cruz Biotechnology). Membranes were then washed and incubated with HRP-conjugated donkey anti-rabbit IgG (Amersham Biosciences).

Myeloperoxidase (MPO) assay

The presence of MPO, an enzyme specific for neutrophils, was used as an index of neutrophil accumulation in the liver (14). Briefly, the frozen tissue was thawed and placed in 4 ml of iced 0.5% hexadecyltrimethyl-ammonium bromide and 50 mM potassium phosphate buffer solution with the pH adjusted to 5. Each sample was homogenized for 30 s and centrifuged at 15,000 rpm for 15 min at 4°C. Supernatants were mixed with hydrogen peroxide-sodium acetate and tetramethyl-benzidine solutions. The change in absorbance was measured spectrophotometrically at 655 nm. One unit of MPO activity was defined as the quantity of enzyme degrading 1 µmol peroxide/min/g of tissue at 25°C.

Statistical analysis

All values are expressed as mean ± SD; data were analyzed with an unpaired two-tailed Student’s t test, and p < 0.05 was considered statistically significant.

	Results

Top Abstract Introduction Materials and Methods Results Discussion Disclosures References

 
The development of IRI in syngeneic OLT

Transplanted organs experience "warm" ischemia during organ procurement and surgery, and "cold" ischemia during organ storage and transfer. Moreover, transplantation itself triggers a certain stress, which may alter gene expression profiles. Thus, we first set-up a series of rat OLT groups in which LEW livers were harvested and stored in UW solution at 4°C for varying periods (0, 24, 30, 36 h) before being transplanted into syngeneic LEW recipients (15, 16). One hundred percent of recipients receiving 0 or 24 h cold-preserved OLTs survived long-term (>50 days; n = 6; data not shown). However, livers stored for 36 h suffered irreversible and lethal injury, as evidenced by 100% recipient death within 48 h (n = 6). The recipients received 30-h cold-preserved livers had a 40% survival rate (n = 12), and was used as a "treatment group."

Histological analysis showed that the extent and severity of liver parenchyma damage correlated with cold preservation time, and that the full development of liver IRI was observed after 24-h reperfusion (Fig. 1). At 4 h of reperfusion, 24-h cold-stored OLTs (group no. 24-4) revealed minimal early necrosis with moderate sinusoidal congestion. There were scattered, small hepatocyte clusters with hypereosinophilic cytoplasm and nuclear hypochromasia (Fig. 1, a and b). However, the same livers after 24-h reperfusion (group no. 24-24) developed moderate/severe necrosis with multiple small foci of necrosis composed of clusters of hepatocytes with loss of cellular detail, generally midzonal involving fewer than half of the lobules. There were few large foci of necrosis extending across multiple lobules with periportal sparing (Fig. 1c). Although largely well-preserved at 4-h post-OLT, the 30-h cold-preserved livers after 24 h of reperfusion (group no. 30-24) developed large foci of necrosis extending across multiple lobules (Fig. 1d). In contrast, livers after 36 h of cold storage developed parenchyma perivenular necrosis involving 50% of the lobules as early as 4 h of reperfusion (group no. 36-4; Fig. 1, e and f). Interestingly, the areas of necrosis were associated with increased numbers of inflammatory cells in sinusoids. sALT levels increased in all three OLT groups, as compared with those from native or liver grafts with no cold ischemia (group no. 0-4), indicating that hepatocellular damage did occur already after 4-h reperfusion and in the absence of histological manifestation of liver parenchyma damage (e.g., sALT = 514 ± 186, vs 197 ± 42 U/ml in 24-4 and 0-4 groups, respectively; p < 0.01, n = 6/group; data not shown).

View larger version (101K): [in this window] [in a new window]   FIGURE 1. Histology of rat IRI in OLT samples harvested at 4 or 24 h posttransplant following 24, 30, or 36 h of cold ischemia. a and b, Twenty-four hour cold-preserved OLTs after 4 h of reperfusion (24-4) with minimal necrosis and moderate sinusoidal congestion, scattered, small hepatocyte clusters with hypereosinophilic cytoplasm and nuclear hypochromasia. c, Twenty-four hour cold-preserved OLTs after 24 h of reperfusion (24-24) with moderate/severe necrosis and multiple small foci of necrosis, clusters of hepatocytes with loss of cellular detail, involving fewer than half of the lobules. d, Thirty hour cold-preserved livers after 24 h of reperfusion (30-24) with large foci of necrosis extending across multiple lobules. e and f, Thirty-six hour cold-preserved OLTs at 4 h of reperfusion (36-4) with early parenchyma, perivenular necrosis involving 50% of the lobules, and associated increased numbers of inflammatory cells in sinusoids. g and h, Thirty hour cold-preserved OLTs after anti-CXCR3 Ab treatment at 4 or 24 h of reperfusion (30-4T and 30-24T, respectively) with mild necrosis consisting of multiple small foci involving clusters of 10–20 cells, generally midzonal in approximately one-third of the lobules. H&E staining; a, c, d, e, g, and h, Original magnification, x100; b and f, original magnification, x400. Representative of three to five samples per group for each time point.

To identify gene products involved in the initiation of IRI, we used cDNA microarray to analyze 4-h reperfused OLT samples, which were at the early stage of IRI as shown above; native livers and 0-h cold-preserved OLT (group no. 0–4) served as controls. Microarray data were uploaded to www.GeneSifter.Net, and pairwise analysis of expression data from 24- vs 36-h preserved OLT was performed to identify differentially expressed gene products, particularly those related to immune activation. Data from each liver sample were normalized to its own global mean expression levels. Four hundred and forty genes were found to have significant changes (2-fold) between these two groups. KEGG (Kyoto Encyclopedia Genes and Genomics) pathway analysis of this gene list revealed two molecular signaling pathways affected the most by z-score: MAP signaling, and TLR signaling, which is consistent with our recent finding that TLR4 signaling is critical in triggering liver IRI cascade (7). There were six chemotaxis-related genes identified by gene ontology analysis. CXCL10 (IP-10, IFN-inducible protein 10) was the most up-regulated one (10-fold increase) associated with T cell chemotaxis. As warm ischemia and surgical procedure itself did not trigger its up-regulation, the cold ischemia was the key factor in CXCL10 induction (group no. 0–4 vs group no. 24-4, Fig. 2a). The extent of CXCL10 gene induction was correlated with the length of cold ischemia time (group no. 24-4 vs group no. 30-4 vs group no. 36-4). We confirmed IR-mediated intrahepatic induction of CXCL10 by using quantitative RT-PCR (see Fig. 4) and immunohistology analyses (Fig. 2b). Among other chemotaxis or immune-related genes associated with lethal liver IRI after 36 h of cold storage, IL-6, CXCL1 (KC, MIP-2), CCL2 (MCP-1), LIX, iNOS and IL-1b were also significantly up-regulated (Fig. 3). CXCL1, in particular, was expressed in livers at very high levels, similar to CXCL10. However, unlike CXCL10, its induction was initiated by warm and further increased by cold ischemia (group no. 0–4 vs group no. 24-4, Fig. 3).

View larger version (91K): [in this window] [in a new window]   FIGURE 2. IP-10 expression in OLT groups by (a) microarray data: average ± SD (n = 2/group) after normalized to global means; b, immunohistology staining (anti-IP-10 Ab and control Ig). OLTs were harvested at 4 h posttransplant after hepatic cold ischemia ranging from 0 to 36 h.

View larger version (13K): [in this window] [in a new window]   FIGURE 4. CXCR3 ligand expression in OLT groups by quantitative RT-PCR. Gene expression by ratios of target gene/-actin (average ± SD; n = 2/group) were plotted with Microsoft Excel.

View larger version (23K): [in this window] [in a new window]   FIGURE 3. Cytokine/chemokine expression in OLT groups by microarray analysis. Gene expression by average ± SD (n = 2/group) after normalized to global means were plotted using the Genesifter.net tool at www.Genesifter.net.

CXCL10 signals through a G-protein-coupled receptor, CXCR3 expressed on activated T cells, and is capable to initiate T cell chemotaxis. There are two other CXCR3 ligands, CXCL9 (monokine induced by IFN-) and CXCL11 (IFN-inducible T cell chemoattractant), which may also affect CXCR3⁺ T cell recruitment. As rat U34 array does not provide their expression data, we undertook quantitative RT-PCR to assess CXCL 9 and 11 levels in our model. As shown in Fig. 4, cold ischemia induced expression of both genes, similarly to CXCL10. However, the extent of CXCL11 induction did not correlate well with the cold preservation time. Thus, to inhibit T cell recruitment into livers, we reasoned that targeting their shared CXCR3 could be more effective than neutralizing any single CXCR3 chemokine alone. A rabbit anti-CXCR3 serum (13) was administered to LEW rats of 30-h cold-preserved OLTs. As shown in Fig. 5, 40% of untreated or normal rabbit serum-treated OLT recipients survived long-term (n = 6–10 rats/group). The CXCR3 blockade improved OLT survival to 95% (p < 0.01). Histological analysis of liver samples harvested at 4- and 24-h posttransplant showed that Ab treatment prevented development of severe hepatic necrosis. There was only mild necrosis with multiple small foci involving clusters of 10–20 cells, generally midzonal in approximately one-third of the lobules (Fig. 1, g and h).

View larger version (8K): [in this window] [in a new window]   FIGURE 5. OLT recipient survival. LEW livers were stored at 4°C in UW solution for 30 h before transplantation into rat syngeneic recipients. Recipients were treated with rabbit anti-rat CXCR3 serum or normal rabbit serum twice: 24 h prior and at the time of liver transplantation (1 ml/injection). Rat survival was monitored daily; n = 6–12 rats/group.

View larger version (71K): [in this window] [in a new window]   FIGURE 6. Impact of anti-CXCR3 serum treatment on peripheral lymphocytes in vivo. a, PBLs were harvested from normal LEW rats, and stained with anti-murine CXCR3 serum (first panel), or a commercial anti-CXCR3 (third panel) rabbit polyclonal Ab. PBLs were harvested 24 h after i.v. infusion of 1 ml of anti-CXCR3 serum, and stained with a FITC-labeled anti-rabbit Ig (second panel). The frequency of CD4 expression was screened in parallel. b, PBLs were harvested before as well as 4 h, and 24 h after i.v. administration of anti-CXCR3 serum. Cells were stained with anti-CD4, anti-CD8, and commercial anti-CXCR3 polyclonal Abs. Lymphocytes were gated for the analysis of total CD4, CD4CXCR3+, and total CD8, CD8 CXCR3+ ratios. Results are representative of three different experiments.

View larger version (136K): [in this window] [in a new window]   FIGURE 7. Immunopathology of rat liver IRI after anti-CXCR3 Ab treatment. Gene expression was analyzed in OLT samples harvested at 4 h or 7 days posttransplant following 30 h of cold ischemia. a–c, Anti-CXCR3 Ab therapy did not abolish IP-10 induction by hepatocytes at 4 h; it had essentially fallen to trace levels by 7 days of follow-up. d–f, Levels of CD4+ T cells were higher in IgG-treated rats than in those receiving anti-CXCR3 Ab. g–i, Numbers of CXCR3+ leukocytes were markedly increased in the IgG-treated group. j–l, Numbers of CD8+ T cells were comparable between groups. No staining was seen using control IgG or after peptide absorption of polyclonal Abs; data for IP-10 controls are shown as insets in each panel. (Cryostat sections labeled by immunoperoxidase and counterstained with hematoxylin; original magnification x150). Representative of three to four samples per group per time point.

To investigate the molecular mechanism of the CXCR3-targeted therapy in ameliorating liver IRI, we applied microarray analysis to identify genes altered by the treatment in the 30-h cold-preserved OLTs. By pairwise comparison of the treated (group no. 30-4T) and control (group no. 30-4) livers, 172 genes were identified to have at least 2-fold changes between the two groups. KEGG pathway analysis of this gene list by z-score revealed that three molecular/cellular pathways were affected the most: cytokine-cytokine receptor interaction, apoptosis, and TLR-signaling pathway. Bcl2-like 11 was down-regulated by 2-fold, and wild-type p53-induced gene 1 x 10-fold. CCL3 and CCL4, which bind to CCR1, CCR5 and are associated with wide-range lymphocyte chemotaxis, were up-regulated by the treatment (Fig. 3). IL-1 and IL-6 were also up-regulated. Interestingly, some of the genes associated with lethal IRI, including CXCL10, CXCL1, CCL2, and LIX, were all up-regulated by the treatment (Fig. 3), indicating a fully activated status of innate immunity in the liver despite CXCR3 Ab treatment. To further investigate the effects of CXCR3-targeted therapy on innate immune activation, we measured innate immune activation gene products at both 4 h and 24 h after reperfusion in OLTs by quantitative RT-PCR. As shown in Fig. 8, innate immune activation products were induced most significantly at 4 h, and all but CD86 declined by 24 h. CXCR3 Ab treatment did not down-regulate their induction seen otherwise during untreated IRI. Additionally, MPO assay, which reflects neutrophil infiltration, showed increased enzymatic activity at 4 h in both control and treated livers (p < 0.01, vs native livers); there was a decline in MPO activity at 24 h in the treated OLTs (Fig. 9). Thus, although CXCR3-targeted therapy did not suppress innate immune activation early during liver IR, it did prevent the development of hepatocellular damage, indicating that the execution of innate immune function in liver IRI required CXCR3⁺CD4⁺ T cells.

View larger version (24K): [in this window] [in a new window]   FIGURE 8. Gene expression of innate immune activation products in OLT groups by quantitative RT-PCR. Gene expression by ratios of target gene/-actin (average ± SD; n = 2/group) were plotted with Microsoft Excel.

View larger version (8K): [in this window] [in a new window]   FIGURE 9. Intrahepatic neutrophil accumulation in ischemic lobes at 4, or 24 h of reperfusion, as analyzed by myeloperoxidase (MPO) enzymatic activity (international units per gram). There were two to four animals per group. Means and SD are shown.

	Discussion

Top Abstract Introduction Materials and Methods Results Discussion Disclosures References

The interlocked roles of proinflammatory cytokines in IRI have been extensively studied. Increased TNF- and IL-1 plasma levels were observed as early as 5 min of liver reperfusion (17). Their functional role was confirmed by neutralization experiments in which IL-1 or TNF- blockade ameliorated the severity of IRI (18, 19). Because IRI develops in the absence of exogenous Ags, most attention in chemokine studies has been focused on those targeting Ag nonspecific leukocytes, in particular macrophages and neutrophils (20). IL-8 (CXCL8 or CINC in rodents), LIX, and MIP-2, are all involved in neutrophil trafficking, and their neutralization was protective in lung, kidney, and myocardial IRI models (21, 22, 23, 24). Recently, small molecule-mediated blockade of CXCR1/CXCR2, the neutrophil chemokine receptors that bind IL-8/MIP-2, reduced granulocyte infiltration and mitigated rat kidney and liver IRI (25, 26). Similar effects were recorded in myocardial IRI model by using CXCR2-deficient mice (27). Chemokines targeted to monocytes, such as MCP-1, have also proven to be critical in renal IRI, as evidenced by tubular cytoprotection in CCR2 (binds MCP-1) deficient mice (28). Despite confirmed roles of these proinflammatory cytokines/chemokines in IRI, the regulation of their induction during IRI and mechanisms of their action other than effects on lymphocyte infiltration have not been fully addressed. In particular, the cascade of proinflammatory chemokine/cytokine programs during IR, and the inflammation status altered by the absence of any of these chemokines or their receptors has not been studied in a comprehensive manner.

Our study is the first that used a systemic approach, i.e., microarray, to identify not only genes induced during liver IRI, but also those altered by anti-CXCR3 Ab treatment. Results show that IR-induced hepatic induction of IL-1 did not correlate with the severity of liver injury. Interestingly, CXCR3-targeted therapy did not decrease, but actually increased IL-1 levels without causing hepatocellular damage. In parallel, IR-induced neutrophil and monocyte targeted chemokines, such as CCL-2, CCL-3, CCL-4, CXCL1 or LIX were readily detectable in our model, and anti-CXCR3 Ab treatment did not inhibit their expression. Consistent with the chemokine expression data, we did find increased neutrophil infiltration (assessed by hepatic MPO activity) at 4-h posttransplant despite anti-CXCR3 Ab treatment. These results indicate that depletion of CXCR3⁺ cells blocked the development of inflammation response without affecting the initial innate immune activation by liver IRI. This implies that the execution of IR-activated innate immune function requires CXCR3⁺ T cells, which may regulate either the responsiveness of neutrophil/monocytes to their chemokines, or the functions of subsequently recruited and activated innate immune cells. Indeed, in the absence of CXCR3⁺ T cells, IR failed to trigger hepatocellular damage despite activation of the innate immune system.

T cells have been shown to play a key role in the mechanism of IRI. Indeed, in the absence of T cells, in particular CD4 T cells, both livers and kidneys are largely protected from IRI (9, 10). Interestingly, concomitant neutrophil infiltration was also reduced in the ischemic livers (9). The question arises how Ag-specific T cells are being recruited into this, by definition Ag-independent inflammatory immune reaction? Our finding that liver IR induced CXCR3 ligands very early (4 h) after reperfusion, provides a clue to this question. The reduction of CD4 and CD8 infiltration after CXCR3 blockade further supports the idea that CXCR3 ligands are responsible for local T cell recruitment in OLTs. Furthermore, our results suggest that intrahepatic accumulation of CXCR3⁺ T cells plays a key role in the pathogenesis of liver IRI. CXCR3 is being expressed mostly on preactivated T cells (memory), particularly Th1, and some NK and B cells (29, 30). Our data that CXCR3⁺ cells are critical in the mechanism of liver IRI is consistent with previously shown cytoprotection against hepatic and renal IRI in Stat4- or Th1-type deficient mice (31, 32). Although type-1 proinflammatory T cells produce IL-2, IFN-, and TNF-, and support macrophage activation (33), we failed to detect the induction of these cytokines in our OLT model (data not shown). This might be due to the lack of sufficient T cell stimulation during liver IRI, in which no specific Ags are present or potent enough to provide the first signal for full T cell activation. This raises an intriguing question as to how T cells function to promote IRI without being fully activated? Our preliminary data suggest a role of TRAIL, which may be expressed constitutively on activated T cells (data not shown). Additionally, we have shown that CD154 costimulatory pathway is critical for the development of IRI in a mouse liver ischemia model (12). Indeed, CD154 expressed on activated CD4 T cells, may also be involved in the activation of liver DCs and/or macrophages (Kupffer cells) via CD40.

One obvious question is which mechanism triggers intrahepatic induction of CXCR3 ligands in the absence of any detectable IFN- in livers early during IR. Although this question remained beyond the scope of this study, our recent data in a mouse liver ischemia model indicate that TLR4 activation might represent the initiating event (7). We have also shown that MyD88-independent signaling downstream of TLR4 mediated by IRF3 is critical for the development of IR-induced hepatocellular damage. IFN-, one of the major players along this pathway (34), can then stimulate multiple liver cell types to elaborate CXCR3 ligands (data not shown).

In conclusion, this study demonstrates a novel mechanism of T cell recruitment and function in the absence of exogenous Ag stimulation. By documenting that the execution of innate immune function requires CXCR3⁺CD4⁺ T cells, it highlights the critical role of CXCR3 chemokine biology for the continuum of innate to adaptive immunity in the pathophysiology of liver IRI.

	Disclosures

Top Abstract Introduction Materials and Methods Results Discussion Disclosures References

 
The authors have no financial conflict of interest.

	Footnotes

 
The costs of publication of this article were defrayed in part by the payment of page charges. This article must therefore be hereby marked advertisement in accordance with 18 U.S.C. Section 1734 solely to indicate this fact.

¹ This work was supported by National Institutes of Health Grants RO1 DK062357, AI23847, and AI42223 (to J.W.K.-W.), The Roche Transplantation Foundation Grant (to Y.Z.), and The Dumont Research Foundation.

² Address correspondence and reprint requests to Dr. Jerzy W. Kupiec-Weglinski, The Dumont-UCLA Transplant Center, 77-120 CHS, Box 957054, 10833 Le Conte Avenue, Los Angeles, CA 90095. E-mail address: jkupiec{at}mednet.ucla.edu

³ Abbreviations used in this paper: IR, ischemia-reperfusion; IRI, IR injury; OLT, orthotopic liver transplantation; MPO, myeloperoxidase; iNOS, inducible NO synthase; sALT, serum alanine aminotransferase.

Received for publication September 8, 2005. Accepted for publication February 27, 2006.

	References

Top Abstract Introduction Materials and Methods Results Discussion Disclosures References

 

1. Laskowski, I., J. Pratschke, M. J. Wilhelm, M. Gasser, N. L. Tilney. 2000. Molecular and cellular events associated with ischemia/reperfusion injury. Ann. Transplant. 5: 29-35. [Medline]
2. Farmer, D., F. Amersi, J. W. Kupiec-Weglinski, R. W. Busuttil. 2000. Current status of ischemia and reperfusion injury in the liver. Transplant. Rev. 14: 106-126.
3. Fellstrom, B., L. M. Akuyrek, U. Backman, E. Larsson, J. Melin, L. Zezina. 1998. Postischemic reperfusion injury and allograft arteriosclerosis. Transplant. Proc. 30: 4278-4280. [Medline]
4. Howard, T. K., G. B. Klintmalm, J. B. Cofer, B. S. Husberg, R. M. Goldstein, T. A. Gonwa. 1990. The influence of preservation injury on rejection in the hepatic transplant recipient. Transplantation 49: 103-107. [Medline]
5. Jaeschke, H.. 2003. Molecular mechanisms of hepatic ischemia-reperfusion injury and preconditioning. Am. J. Physiol. 284: G15-G26.
6. Fondevila, C., R. W. Busuttil, J. W. Kupiec-Weglinski. 2003. Hepatic ischemia/reperfusion injury—a fresh look. Exp. Mol. Pathol. 74: 86-93. [Medline]
7. Zhai, Y., X. D. Shen, R. O’Connell, F. Gao, C. Lassman, R. W. Busuttil, G. Cheng, J. W. Kupiec-Weglinski. 2004. Cutting edge: TLR4 activation mediates liver ischemia/reperfusion inflammatory response via IFN regulatory factor 3-dependent MyD88-independent pathway. J. Immunol. 173: 7115-7119. [Abstract/Free Full Text]
8. Rabb, H.. 2002. The T cell as a bridge between innate and adaptive immune systems: implications for the kidney. Kidney Int. 61: 1935-1946. [Medline]
9. Zwacka, R. M., Y. Zhang, J. Halldorson, H. Schlossberg, L. Dudus, J. F. Engelhardt. 1997. CD4⁺ T-lymphocytes mediate ischemia/reperfusion-induced inflammatory responses in mouse liver. J. Clin. Invest. 100: 279-289. [Medline]
10. Rabb, H., F. Daniels, M. O’Donnell, M. Haq, S. R. Saba, W. Keane, W. W. Tang. 2000. Pathophysiological role of T lymphocytes in renal ischemia-reperfusion injury in mice. Am. J. Physiol. 279: F525-F531.
11. Yokota, N., F. Daniels, J. Crosson, H. Rabb. 2002. Protective effect of T cell depletion in murine renal ischemia-reperfusion injury. Transplantation 74: 759-763. [Medline]
12. Shen, X. D., B. Ke, Y. Zhai, F. Amersi, F. Gao, D. M. Anselmo, R. W. Busuttil, J. W. Kupiec-Weglinski. 2002. CD154-CD40 T-cell costimulation pathway is required in the mechanism of hepatic ischemia/reperfusion injury, and its blockade facilitates and depends on heme oxygenase-1 mediated cytoprotection. Transplantation 74: 315-319. [Medline]
13. Belperio, J. A., M. P. Keane, M. D. Burdick, J. P. Lynch, 3rd, Y. Y. Xue, K. Li, D. J. Ross, R. M. Strieter. 2002. Critical role for CXCR3 chemokine biology in the pathogenesis of bronchiolitis obliterans syndrome. J. Immunol. 169: 1037-1049. [Abstract/Free Full Text]
14. Mullane, K. M., R. Kraemer, B. Smith. 1985. Myeloperoxidase activity as a quantitative assessment of neutrophil infiltration into ischemic myocardium. J. Pharmacol. Methods 14: 157-167. [Medline]
15. Amersi, F., R. Buelow, H. Kato, B. Ke, A. J. Coito, X. D. Shen, D. Zhao, J. Zaky, J. Melinek, C. R. Lassman, et al 1999. Upregulation of heme oxygenase-1 protects genetically fat Zucker rat livers from ischemia/reperfusion injury. J. Clin. Invest. 104: 1631-1639. [Medline]
16. Anselmo, D. M., F. F. Amersi, X. D. Shen, F. Gao, M. Katori, C. Lassman, B. Ke, A. J. Coito, J. Ma, V. Brinkmann, et al 2002. FTY720 pretreatment reduces warm hepatic ischemia reperfusion injury through inhibition of T-lymphocyte infiltration. Am. J. Transplant. 2: 843-849. [Medline]
17. Suzuki, S., L. H. Toledo-Pereyra. 1994. Interleukin 1 and tumor necrosis factor production as the initial stimulants of liver ischemia and reperfusion injury. J. Surg. Res. 57: 253-258. [Medline]
18. Shirasugi, N., G. Wakabayashi, M. Shimazu, A. Oshima, M. Shito, S. Kawachi, T. Karahashi, Y. Kumamoto, M. Yoshida, M. Kitajima. 1997. Up-regulation of oxygen-derived free radicals by interleukin-1 in hepatic ischemia/reperfusion injury. Transplantation 64: 1398-1403. [Medline]
19. Shito, M., G. Wakabayashi, M. Ueda, M. Shimazu, N. Shirasugi, M. Endo, M. Mukai, M. Kitajima. 1997. Interleukin 1 receptor blockade reduces tumor necrosis factor production, tissue injury, and mortality after hepatic ischemia-reperfusion in the rat. Transplantation 63: 143-148. [Medline]
20. Koo, D. D. H., S. V. Fuggle. 2002. Chemokines in ischemia/reperfusion injury. Curr. Opin. Organ Transplant. 7: 100-106.
21. Sekido, N., N. Mukaida, A. Harada, I. Nakanishi, Y. Watanabe, K. Matsushima. 1993. Prevention of lung reperfusion injury in rabbits by a monoclonal antibody against interleukin-8. Nature 365: 654-657. [Medline]
22. Boyle, E. M., Jr, J. C. Kovacich, C. A. Hebert, T. G. Canty, Jr, E. Chi, E. N. Morgan, T. H. Pohlman, E. D. Verrier. 1998. Inhibition of interleukin-8 blocks myocardial ischemia-reperfusion injury. J. Thorac. Cardiovasc. Surg. 116: 114-121. [Abstract/Free Full Text]
23. Chandrasekar, B., J. B. Smith, G. L. Freeman. 2001. Ischemia-reperfusion of rat myocardium activates nuclear factor-B and induces neutrophil infiltration via lipopolysaccharide-induced CXC chemokine. Circulation 103: 2296-2302. [Abstract/Free Full Text]
24. Miura, M., X. Fu, Q. W. Zhang, D. G. Remick, R. L. Fairchild. 2001. Neutralization of Gro and macrophage inflammatory protein-2 attenuates renal ischemia/reperfusion injury. Am. J. Pathol. 159: 2137-2145. [Abstract/Free Full Text]
25. Bertini, R., M. Allegretti, C. Bizzarri, A. Moriconi, M. Locati, G. Zampella, M. N. Cervellera, V. Di Cioccio, M. C. Cesta, E. Galliera, et al 2004. Noncompetitive allosteric inhibitors of the inflammatory chemokine receptors CXCR1 and CXCR2: prevention of reperfusion injury. Proc. Natl. Acad. Sci. USA 101: 11791-11796. [Abstract/Free Full Text]
26. Cugini, D., N. Azzollini, E. Gagliardini, P. Cassis, R. Bertini, F. Colotta, M. Noris, G. Remuzzi, A. Benigni. 2005. Inhibition of the chemokine receptor CXCR2 prevents kidney graft function deterioration due to ischemia/reperfusion. Kidney Int. 67: 1753-1761. [Medline]
27. Tarzami, S. T., W. Miao, K. Mani, L. Lopez, S. M. Factor, J. W. Berman, R. N. Kitsis. 2003. Opposing effects mediated by the chemokine receptor CXCR2 on myocardial ischemia-reperfusion injury: recruitment of potentially damaging neutrophils and direct myocardial protection. Circulation 108: 2387-2392. [Abstract/Free Full Text]
28. Furuichi, K., T. Wada, Y. Iwata, K. Kitagawa, K. Kobayashi, H. Hashimoto, Y. Ishiwata, M. Asano, H. Wang, K. Matsushima, et al 2003. CCR2 signaling contributes to ischemia-reperfusion injury in kidney. J. Am. Soc. Nephrol. 14: 2503-2515. [Abstract/Free Full Text]
29. Homey, B., A. Muller, A. Zlotnik. 2002. Chemokines: agents for the immunotherapy of cancer?. Nat. Rev. Immunol. 2: 175-184. [Medline]
30. Sallusto, F., A. Lanzavecchia, C. R. Mackay. 1998. Chemokines and chemokine receptors in T-cell priming and Th1/Th2-mediated responses. Immunol. Today 19: 568-574. [Medline]
31. Shen, X. D., B. Ke, Y. Zhai, F. Gao, D. Anselmo, C. R. Lassman, R. W. Busuttil, J. W. Kupiec-Weglinski. 2003. Stat4 and Stat6 signaling in hepatic ischemia/reperfusion injury in mice: HO-1 dependence of Stat4 disruption-mediated cytoprotection. Hepatology 37: 296-303. [Medline]
32. Yokota, N., M. Burne-Taney, L. Racusen, H. Rabb. 2003. Contrasting roles for STAT4 and STAT6 signal transduction pathways in murine renal ischemia-reperfusion injury. Am. J. Physiol. 285: F319-F325.
33. Liblau, R. S., S. M. Singer, H. O. McDevitt. 1995. Th1 and Th2 CD4⁺ T cells in the pathogenesis of organ-specific autoimmune diseases. Immunol. Today 16: 34-38. [Medline]
34. Takeda, K., T. Kaisho, S. Akira. 2003. Toll-like receptors. Annu. Rev. Immunol. 21: 335-376. [Medline]

This article has been cited by other articles:

				B. Vollmar and M. D. Menger The Hepatic Microcirculation: Mechanistic Contributions and Therapeutic Targets in Liver Injury and Repair Physiol Rev, October 1, 2009; 89(4): 1269 - 1339. [Abstract] [Full Text] [PDF]

				K. Shimizu and R. N. Mitchell The Role of Chemokines in Transplant Graft Arterial Disease Arterioscler Thromb Vasc Biol, November 1, 2008; 28(11): 1937 - 1949. [Abstract] [Full Text] [PDF]

				J. A Belperio and A. Ardehali Chemokines and Transplant Vasculopathy Circ. Res., August 29, 2008; 103(5): 454 - 466. [Abstract] [Full Text] [PDF]

				C. C. Caldwell, J. Tschoep, and A. B. Lentsch Lymphocyte function during hepatic ischemia/reperfusion injury J. Leukoc. Biol., September 1, 2007; 82(3): 457 - 464. [Abstract] [Full Text] [PDF]

				R. T. Emeny, D. Gao, and D. A. Lawrence beta1-Adrenergic Receptors on Immune Cells Impair Innate Defenses against Listeria J. Immunol., April 15, 2007; 178(8): 4876 - 4884. [Abstract] [Full Text] [PDF]

This Article Abstract Full Text (PDF) Alert me when this article is cited Alert me if a correction is posted Citation Map Services Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Request Permissions Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Zhai, Y. Articles by Kupiec-Weglinski, J. W. Search for Related Content PubMed PubMed Citation Articles by Zhai, Y. Articles by Kupiec-Weglinski, J. W.